Indefinite Delivery Contract SPE2DR25D3303

This Indefinite Delivery Contract (IDC) SPE2DR25D3303, awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, is a comprehensive pharmaceutical supply contract valued at $999,999,999 through December 2026. The contract encompasses a broad range of medical commodities, including specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits across multiple therapeutic areas such as cardiovascular health, diabetes management, mental health, pain management, infectious disease prevention, and general medical care. This IDC serves as a primary vehicle for providing pharmaceutical products and medical supplies to support military healthcare programs globally, covering both normal day-to-day operations and contingency/readiness requirements for the DoD, Coast Guard, and other government agencies.

The original solicitation, which is expected to be issued in March 2024, seeks to establish Pharmaceutical Prime Vendor Global Program Generation V contracts to provide worldwide pharmaceutical support. The Government intends to make multiple primary supplier awards on a regional basis (North/EUCOM, West/PACOM, South/SOUTHCOM, and Fleet) as well as a separate award for a backup supplier, with the goal of having at least three different contractors to ensure resiliency and access to vital pharmaceuticals. The contract will be a firm-fixed price, requirements-type contract with a 30-month base period and three 30-month option periods, and will be awarded using a Lowest Price Technically Acceptable (LPTA) evaluation approach.